CYP2B1/2B2 Antibody (9.20): sc-73547
- CYP2B1/2B2 Antibody (9.20) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against liver cytochromes P450 2B1 and 2B2 of rat origin
- recommended for detection of CYP2B1 and CYP2B2 of mouse and rat origin by WB
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CYP2B1/2B2 Antibody (9.20). This work is in progress.
CYP2B1/2B2 Antibody (9.20) is a mouse monoclonal IgG1 antibody that detects CYP2B1/2B2 in mouse and rat samples through western blotting (WB). CYP2B1 and CYP2B2 are crucial members of the cytochrome P450 (CYP2) superfamily, which plays a significant role in the metabolism of various endogenous and exogenous compounds, including therapeutic agents and fatty acids. These enzymes are primarily located in the liver, where they facilitate the oxidation of substances, thereby influencing drug metabolism and detoxification processes. The importance of their cellular location cannot be overstated, as the liver is the central organ for drug metabolism, and the activity of CYP2B1 and CYP2B2 can significantly affect the pharmacokinetics of drugs, including their efficacy and toxicity. Additionally, CYP2B1 is known to convert ifosfamide into its active cytotoxic metabolites, while CYP2B2 is involved in the induction of phenobarbital, highlighting their roles in both therapeutic and adverse drug reactions. Anti-CYP2B1/2B2 antibody (9.20) is an essential tool for researchers studying drug metabolism and the biochemical pathways involving these critical enzymes.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CYP2B1/2B2 Antibody (9.20) References:
- Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. | Miksys, S., et al. 2000. Biochem Pharmacol. 59: 1501-11. PMID: 10799646
- Sequence analyses of CYP2B genes and catalytic profiles for P450s in Qdj:Sprague-dawley rats that lack response to the phenobarbital-mediated induction of CYP2B2. | Yamada, H., et al. 2000. J Pharmacol Exp Ther. 295: 986-93. PMID: 11082433
- Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer. | Mercadé, E., et al. 2001. Ann Oncol. 12: 379-88. PMID: 11332152
- Metabolism of N,N',N'-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. | Harleton, E., et al. 2004. J Pharmacol Exp Ther. 310: 1011-9. PMID: 15121764
- FMDV-2A sequence and protein arrangement contribute to functionality of CYP2B1-reporter fusion protein. | Lengler, J., et al. 2005. Anal Biochem. 343: 116-24. PMID: 15955524
- Spatial distribution of CYP2B1/2 messenger RNA within the rat liver acinus following exposure to the inducers phenobarbital and dieldrin. | Dail, MB., et al. 2007. Toxicol Sci. 99: 35-42. PMID: 17517822
- Bromuconazole-induced hepatotoxicity is accompanied by upregulation of PXR/CYP3A1 and downregulation of CAR/CYP2B1 gene expression. | Abdelhadya, DH., et al. 2017. Toxicol Mech Methods. 27: 544-550. PMID: 28532222
- Localization of a phenobarbital-responsive element (PBRE) in the 5'-flanking region of the rat CYP2B2 gene. | Trottier, E., et al. 1995. Gene. 158: 263-8. PMID: 7607552
- Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. | Desjardins, J., et al. 1995. J Drug Target. 2: 477-85. PMID: 7773609
- Brain tumor gene therapy in mice with a novel 'suicide' gene: the cyclophosphamide-activating CYP2B1 gene. | Chiocca, EA. 1995. Clin Neurosurg. 42: 370-82. PMID: 8846604
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2B1/2B2 Antibody (9.20) | sc-73547 | 200 µg/ml | $322.00 |